港股异动 | 中生制药(01177)现跌超5% 花旗称少数股东权益百分比被抵估 下调每股盈测
中生制药(01177)现跌超5%，截至发稿，跌5.4%，报2.98港元，成交额8732.6万港元。
消息面上，花旗发表报告指出，维持对中生制药的收入预测不变，但由于少数股东权益百分比被抵估，因此下调对其每股盈利预测，目标价由9港元下调至7.4港元，维持“买入”评级。
汇丰此前指出，公司大部分负面因素已反映在股价之上，考虑到该公司疫苗库存水平较低，估计减值影响有限，并对其增长前景保持乐观。该行认为中生制药增长前景稳固，现价水平为2024年经调整预测市盈率为15倍，较同业平均19倍低，估值有吸引力，维持“买入”评级，因应最新估值，将目标价从5港元降至4.6港元。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.